Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Learn more on PFE stock here.
Le Lézard

ViiV Healthcare's long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced final data from the LATITUDE phase III trial, confirming its ...
Le Lézard

ACTG Announces Publication of LATITUDE Findings in the New England Journal of Medicine

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the publication of "Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges" in ...

The Patent Cliff Is a Hill: Why Merck's Diversification Engine Makes MRK a Buy

The consensus narrative frames Merck as a one-product company facing an existential patent cliff in 2028. Wefundamentally disagree with this characterization. Merck is executing one of the most ...

Halozyme Therapeutics, Inc.: Halozyme Reports Full Year 2025 Record Revenue Of $1.4 Billion And Reiterates Strong 2026 Financial Guidance

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billionFull Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions ...
C&EN

MAHA’s next target: metals in vaccine ingredients

Officials are going after metal-containing ingredients, including aluminum adjuvants. Here’s why vaccines need them ...